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ABSTRACT
Background
Multidrug-resistant tuberculosis (MDR-TB) is an important global health problem, and a
control strategy known as DOTS-Plus has existed since 1999. However, evidence regarding the
feasibility, effectiveness, cost, and cost-effectiveness of DOTS-Plus is still limited.
Methodology/Principal Findings
We evaluated the feasibility, effectiveness, cost, and cost-effectiveness of a DOTS-Plus pilot
project established at Makati Medical Center in Manila, the Philippines, in 1999. Patients with
MDR-TB are treated with regimens, including first- and second-line drugs, tailored to their drug
susceptibility pattern (i.e., individualised treatment). We considered the cohort enrolled
between April 1999 and March 2002. During this three-year period, 118 patients were enrolled
in the project; 117 were considered in the analysis. Seventy-one patients (61%) were cured, 12
(10%) failed treatment, 18 (15%) died, and 16 (14%) defaulted. The average cost per patient
treated was US$3,355 from the perspective of the health system, of which US$1,557 was for
drugs, and US$837 from the perspective of patients. The mean cost per disability-adjusted life
year (DALY) gained by the DOTS-Plus project was US$242 (range US$85 to US$426).
Conclusions
Treatment of patients with MDR-TB using the DOTS-Plus strategy and individualised drug
regimens can be feasible, comparatively effective, and cost-effective in low- and middle-income
countries.
The Editors’ Summary of this article follows the references.
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PLoS MEDICINEIntroduction
Multidrug-resistant tuberculosis (MDR-TB), which is de-
ﬁned as resistance to at least the two most effective ﬁrst-line
anti-TB drugs, rifampicin and isoniazid, is a threat to
tuberculosis (TB) control efforts in some countries [1–3].
Approximately 460,000 cases develop each year, about half of
them among new TB cases and the other half among people
who have been previously treated for TB [4]. When only ﬁrst-
line anti-TB drugs are used, cure rates among patients with
MDR-TB are low: 5%–35% for previously treated cases and
12%–60% for new cases [5], with a relapse rate of 24% [6].
Treatment that includes second-line anti-TB drugs can
considerably improve cure rates [7–20] and reduce trans-
mission, but its availability remains limited in low- and
middle-income countries. This reﬂects the high price of
second-line drugs [21] as well as the (related) emphasis of
national and international TB control efforts on implemen-
tation of the DOTS strategy. The DOTS strategy focuses on
treatment of the approximately nine million new cases of TB
that occur each year with standardized ﬁrst-line drug
regimens, which cure about 90% of patients in the absence
of MDR and cost as little as US$10 per patient [22].
Building on the successes of DOTS, the World Health
Organization (WHO) and partner agencies developed a
strategy for treatment of MDR-TB, termed ‘‘DOTS-Plus,’’ in
1999 [21,23]. The DOTS-Plus strategy adapted the core
components of DOTS to the needs of patients with MDR-
TB, in particular including diagnosis based on culture and
drug susceptibility testing and treatment with second- as well
as ﬁrst-line drugs. As it was recognized that the high price of
second-line drugs would be a major impediment to imple-
mentation of the DOTS-Plus strategy, simultaneous efforts
were made to lower the price of second-line drugs. These
efforts resulted in the Green Light Committee (GLC) [21,24],
which in partnership with pharmaceutical companies is able
to provide second-line drugs at highly concessionary prices to
projects and programmes that meet strict eligibility criteria.
A growing number of low- and middle-income countries
are now implementing DOTS-Plus pilot projects or pro-
grammes, with 33 GLC-approved projects by the end of 2005.
However, evidence about their feasibility, effectiveness, cost,
and cost-effectiveness remains scarce. An evaluation of the
national programme in Peru showed that treatment of
chronic cases, 87% of whom had MDR-TB, was feasible and
cost-effective, though cure rates were relatively low [8].
Published data on treatment outcomes are limited to Latvia,
Peru, and Turkey [8,9,11–13]. More data are required for
policy development, planning, and budgeting at global and
national levels.
In April 1999, a DOTS-Plus pilot project was initiated at
the Makati Medical Center (MMC) in Manila, Philippines [25].
This article assesses the project’s feasibility, effectiveness,
cost, and cost-effectiveness.
Methods
Setting
Philippines is a lower middle income country with a per
capita gross national income of US$1,080 in 2003 [26].
Globally, it ranks eighth in terms of the estimated number
of new TB cases that occur each year, with about 240,000 cases
in 2004 [4]. It is estimated that there are 25,803 MDR-TB cases:
7,238 new cases and 18,565 previously treated cases [3,27].
DOTS is implemented nationally, with a case detection rate
of 73% and a successful treatment rate of 89% for new
smear-positive cases [4], both in excess of WHO targets.
DOTS treatment involves a four-drug ﬁrst-line regimen for
new cases, and a ﬁve-drug retreatment regimen for patients
who fail treatment with this ﬁrst regimen or who have had TB
before and have suffered a relapse. Patients who fail the
retreatment regimen are deﬁned as chronic cases [28], and as
of March 2006, no treatment was available for them in the
public sector. Treatment in the private sector is generally of
unknown quality and limited by patients willingness and
ability to pay.
MMC is a private tertiary hospital in the main commercial
district of Manila. It established DOTS services in 1999, in
partnership with the Department of Health and the local
government [29]. A DOTS-Plus pilot project was started in
April 1999. In March 2006, MMC remained the only facility in
the country offering such treatment.
Description of the DOTS-Plus Pilot Project
Two major categories of TB cases were eligible for
treatment in the DOTS-Plus project: (a) chronic cases of
MDR-TB referred from public or private facilities; and (b)
cases with a diagnosis of MDR-TB during treatment with the
ﬁrst-line retreatment regimen. A few patients with MDR-TB
identiﬁed among new cases during contact tracing or treat-
ment with ﬁrst-line drugs were also enrolled. Diagnosis was
based on smear and culture examination. After informed
written consent, patients were treated with an individualised
regimen based on drug susceptibility testing results for all
ﬁrst-line drugs, three second-line drugs (kanamycin, cipro-
ﬂoxacin, and oﬂoxacin), and previous use of other drugs as
reported by patients. In the intensive phase of treatment, a
daily ﬁve-drug regimen was used. This typically consisted of
an injectable drug, a ﬂuoroquinolone, other oral second-line
drugs, and ﬁrst-line drugs to which the patient was not
resistant. In the continuation phase, started after six
consecutive months of negative culture results, the injectable
or (occasionally) a noninjectable to which the patient was
intolerant was dropped from the regimen. Treatment was
continued until cultures were negative for 18 consecutive
months. During the intensive phase, direct observation of
treatment (DOT) was provided by MMC staff. In the
continuation phase, alternating clinic and home-based DOT
was used. Patients who defaulted were followed up by
telephone, telegram, and/or home visits.
Patient Cohort Studied
We considered the patient cohort enrolled between 1 April
1999 and 31 March 2002.
Treatment Outcomes
Treatment outcomes for the DOTS-Plus project were
assessed using internationally agreed consensus deﬁnitions
[30]. There were six possible outcomes: cured, completed
treatment, died, defaulted, transferred out of the district and
treatment outcome unknown, and failed treatment. Cure was
deﬁned as having completed at least 18 months of treatment,
with negative cultures in the last month of treatment and
consistent culture-negative status for the previous 11 months.
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have been cured, but bacteriological tests to conﬁrm this
were not available. The outcome ‘‘died’’ was applied for both
TB and non-TB related deaths. Failed meant that the patient
remained culture-positive at the end of treatment.
Cost and Cost-Effectiveness Analysis
Any cost-effectiveness analysis requires comparison of
relevant alternative strategies [31]. We compared the DOTS-
Plus project with the situation that would apply in the
absence of the project, i.e., what would have happened to the
cohort of DOTS-Plus patients had they not been enrolled in
the project. For chronic MDR-TB cases, this meant no
treatment, or limited treatment based on what patients could
afford to pay for in the private sector. For retreatment cases
with MDR-TB, it meant continued use of the standard ﬁrst-
line retreatment regimen. For new cases with MDR-TB, it
meant treatment with the standard ﬁrst-line drug regimen.
Costs were assessed in year 2002 US$ from a societal
perspective (i.e., health system, patient, and family costs were
considered) using standard methods [31,32].
For the DOTS-Plus project, two types of costs were
considered: (a) the average cost of individual components of
treatment (e.g., drugs, a DOT visit); and (b) the average cost
per patient treated. The costs of individual components of
treatment were calculated using an ‘‘ingredients’’ approach,
i.e., the quantity of resources used was multiplied by unit
prices. Joint costs (e.g., clinic staff that spent time on both
DOTS and DOTS-Plus patients) were allocated according to
the time spent on each group of patients. Vehicle and
equipment costs were annualised using current replacement
prices, the assumption of a ﬁve-year life expectancy, and a
discount rate of 3% [33]. Startup training costs were
annualised over three years. Building costs per year were
based on rental values per month. All local costs were
converted into US$ using the average exchange rate in 2002
(US$1 ¼ PhP 50.9). The average cost per patient treated was
calculated as the cost of each treatment component multi-
plied by the average number of times this cost was incurred.
Sources of data included expenditure records, interviews with
staff and patients, project records and databases, and the
GLC secretariat.
To assess treatment costs for chronic cases in the absence
of a DOTS-Plus project, all retreatment failures registered in
three administrative units of Metro Manila during 2000 and
2001 were identiﬁed. The three areas were purposively
selected based on good DOTS programme performance and
a large population size. The 46 treatment failures that were
identiﬁed were traced, and they or a close relative (if the
patient had died) interviewed about any further treatment
that had been taken and related expenditures, using a
standardized structured questionnaire. Costs for new and
retreatment cases were estimated using national data
reported to WHO [4].
Given uncertainty about several parameters that inﬂuence
effectiveness, which in turn affects both total costs and cost-
effectiveness, we estimated these three indicators as part of a
multivariate uncertainty analysis. For consistency and com-
parability, this analysis was based on the same principles and
much of the data that were used in the evaluation of the
MDR-TB treatment programme in Peru, full details of which
are available elsewhere [8]. In brief, the analysis was designed
to measure the effectiveness of each strategy in terms of cases
cured, deaths averted, and DALYs gained, and to capture
both (a) effects among the patient cohort treated and (b) the
effect of treatment of this cohort on transmission, and hence
the number of cases, deaths, and DALYs gained that occur in
the future. The analysis used an Excel spreadsheet model in
which treatment paths were deﬁned for the two alternative
strategies (i.e., DOTS-Plus available, and DOTS-Plus not
available). For each strategy, treatment paths were deﬁned
for chronic, retreatment, and new MDR-TB cases separately.
The number of patients following each treatment path,
together with their associated costs and effects, was deﬁned
according to (a) the parameters, parameter distributions, and
data sources listed in Protocol S1 [2,4,5,34–43], (b) the costs
per patient reported in this article, and (c) the treatment
outcomes associated with the DOTS-Plus project, also
reported in this article. As shown in Protocol S1, treatment
outcomes for chronic cases when DOTS-Plus is not available
were estimated from long-term follow-up studies of chronic
cases in Korea, Vietnam, and the Russian Federation, and
natural history studies. These outcomes were also assumed to
apply to patients who defaulted from DOTS-Plus treatment.
Long-term outcomes for patients treated in a DOTS-Plus
project, including those who failed treatment or who relapsed
after cure, were based on a study of MDR-TB patients with
ten-year follow-up in the United States. Treatment outcomes
for MDR-TB cases on ﬁrst-line regimens were based on a
multi-country study. A Monte Carlo simulation involving
5,000 iterations was used to estimate means, and lower and
upper bounds (ﬁfth and ninety-ﬁfth centiles) for the main
outputs of interest, i.e., the total costs and total DALYs lost
for each strategy, the total DALYs gained by DOTS-Plus, and
the cost per DALY gained by DOTS-Plus.
Statistical Analysis
In addition to the uncertainty analysis described above, we
compared the clinical and demographic characteristics of the
cohort enrolled in treatment with patients who were eligible
but not enrolled in treatment, using chi-square tests for
categorical outcome variables and t-tests for continuous
outcome variables. We also used the chi-square test to
compare the treatment outcomes of chronic cases with those
of new and retreatment cases. Given the small number of new
cases (n ¼ 5), we combined new and retreatment cases in one
category when making comparisons with chronic cases.
Results
Patient Enrollment and Characteristics
Between April 1999 and March 2002, 219 cases were
evaluated. Among these cases, 171 were conﬁrmed to have
MDR-TB. Of these 171 cases that were eligible for MDR-TB
treatment, 118 were enrolled in the DOTS-Plus project, and
117 were considered in the analysis (Figure 1). A comparison
of the 118 enrolled patients with the 53 considered eligible
but who were not enrolled showed no signiﬁcant difference
in key characteristics such as age, sex, and number of previous
treatments (Protocol S2). There was a signiﬁcant difference in
the percentage that were resistant to ﬁve or more drugs (p ,
0.001), with more of those enrolled being resistant to ﬁve or
more drugs, and in place of residence with more of those
enrolled residing in Makati (p ¼ 0.05).
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1. Ninety were chronic cases, and 27 were new or retreatment
cases. The average age was 38 years; 86 (74%) were male. The
average income was US$31 per month (range US$0–US$625),
and the average number of treatment courses before enroll-
ment on DOTS-Plus was 2.8. Many patients (62%) were
resistant to ﬁve or more drugs. Lack of testing services meant
that the HIV status of patients was unknown, but 27 patients
had diseases other than TB: diabetes (n ¼ 17), chronic
obstructive pulmonary disease (n ¼ 3), peptic ulcer (n ¼ 2),
and heart disease (n ¼ 2). Of the 102 patients with X-ray
results, 66 had cavitary disease. Of the 117 patients, 106 had
pulmonary TB and 11 had extrapulmonary TB. The charac-
teristics of chronic cases on the one hand, and new and
retreatment cases on the other, were generally similar. The
main statistically signiﬁcant differences (p   0.05) were that a
much higher proportion of chronic cases had previously been
treated with second-line drugs (p , 0.001), while a relatively
Figure 1. Patient Enrollment in DOTS-Plus Project, 1 April 1999 to 31 March 2002
DOI: 10.1371/journal.pmed.0030352.g001
Table 1. Demographic Characteristics and Disease-Related Variables according to Enrollment Criteria
Variable Entry Criteria
Chronic Cases
(n ¼ 90)
Retreatment Cases
(n ¼ 22)
New Cases
(n ¼ 5)
All Cases
(n ¼ 117)
Sex Male 65 (72%) 18 (82%) 3 (60%) 86 (74%)
Female 25 (28%) 4 (18%) 2 (40%) 31 (26%)
Age in years 15–24 7 (8%) 2 (9%) 2 (40%) 11 (9%)
25–34 29 (32%) 6 (27%) 2 (40%) 37 (32%)
35–44 30 (33%) 7 (32%) 1 (20%) 38 (32%)
45–54 11 (12%) 4 (18%) 0 (0%) 15 (13%)
55þ 13 (14%) 3 (14%) 0 (0%) 16 (14%)
Residence Makati 8 (9%) 12 (55%) 0 (0%) 20 (17%)
Metro Manila 60 (67%) 9 (41%) 4 (80%) 73 (62%)
Outside Manila 22 (24%) 1 (5%) 1 (20%) 24 (21%)
Resistance profile Resistant to 2 or more drugs 3 (3%) 4 (18%) 1 (20%) 8 (7%)
Resistant to 3 or more drugs 9 (10%) 4 (18%) 1 (20%) 14 (12%)
Resistant to 4 or more drugs 16 (18%) 5 (23%) 1 (20%) 22 (19%)
Resistant to 5 or more drugs 62 (69%) 9 (41%) 2 (40%) 73 (62%)
Number of previous treatments 0 0 (0%) 0 (0%) 5 (100%) 5 (4%)
1 10 (11%) 3 (14%) 0 (0%) 13 (11%)
2 25 (28%) 6 (27%) 0 (0%) 31 (27%)
3 or more 55 (61%) 13 (59%) 0 (0%) 68 (58%)
Previous anti-TB drugs None 0 (0%) 0 (0%) 5 (100%) 5 (4%)
First-line drugs only 45 (50%) 19 (86%) 0 (0%) 64 (55%)
First and second-line drugs 45 (50%) 3 (14%) 0 (0%) 48 (41%)
Percentages do not always sum to 100 due to rounding.
DOI: 10.1371/journal.pmed.0030352.t001
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Analysis of DOTS-Plus in the Philippineshigh proportion of new and retreatment cases lived locally, in
Makati (p , 0.001).
Treatment Outcomes and Adverse Events
Treatment outcomes are shown in Table 2. For the entire
cohort, the cure rate was 61% (71/117, including 70 patients
for whom cure was conﬁrmed by bacteriological examination
and one patient who was considered to have been cured but
for whom bacteriological tests to conﬁrm this were not
available). Of the 71 patients cured, 90% had converted to
sputum culture negative status after three months of treat-
ment. Of the 18 patients who died, nine of 14 (64%)
investigated were bacteriologically negative at the time of
death. Among the 16 patients who defaulted, eight of 15
(53%) investigated were bacteriologically negative when they
defaulted. Default rates were lower among chronic cases
compared with new and retreatment cases (p ¼ 0.01).
Adverse events were the main reason for default (11/16).
Two patients cited ﬁnancial difﬁculties; the remaining three
causes were family problems, a decision to return to a home
located in another province, and a hospital discharge that was
made without the endorsement of MMC staff. We could not
identify any clinical variable that was a positive predictor of
cure, though women appeared more likely to be cured than
men.
During treatment, almost all (112/117, or 96%) patients
experienced adverse events (Table 3). Most side-effects were
minor, but serious side-effects such as hearing loss and
depression were also observed. Side-effects were managed
through treatment with ancillary drugs, through temporary
interruption of the drug suspected to be the cause of the
adverse event, or (among 49% of patients) through removing
the suspected drug from the treatment regimen and replac-
ing it with a suitable alternative. The name, class, and
frequency with which drugs were used to treat patients, and
their relationship with adverse events, is shown in Table 4.
Cost and Cost-Effectiveness
The average cost per patient treated in the DOTS-Plus
project was US$4,192, of which US$3,355 was health system
costs and US$837 costs incurred by patients and their families
(Table 5). Drugs, at US$1,557 per patient, were the most
important cost item. At market rather than GLC prices, the
average cost of drugs per patient would have been US$1,343
higher. For patients and their families, costs were mostly for
clinic visits for DOT, and board and lodging. In the absence of
a DOTS-Plus project, the average cost per MDR case was
US$116. The average cost per chronic case was US$100, all
out-of-pocket expenditures by patients. It was US$317 for
retreatment cases and US$235 for new cases, with both costs
roughly split between patients and the health system. Out-of-
pocket expenditures by chronic cases in the private sector
were mostly for prescriptions restricted to ﬁrst-line drugs.
Only six of the 46 chronic cases that were identiﬁed had
prescriptionsforsecond-linedrugs,usuallyaﬂuoroquinolone.
The total costs for each strategy, including both the costs of
the cohort of 117 patients and costs associated with
secondary cases generated through transmission of TB by
this cohort, are shown in Table 6. The net increase in total
costs associated with the DOTS-Plus strategy was about
US$0.4 million, additional costs that resulted in a large
number of averted deaths and DALYs gained (Table 6). The
mean cost per DALY gained by DOTS-Plus from the health
system’s perspective was US$179, and US$242 when all costs
were considered.
Discussion
This study demonstrates that resource-limited settings can
provide individualised treatment including second-line drugs
at an appropriate standard of care for highly resistant MDR-
TB patients: 86% of patients complied with treatment, and
t h ec u r er a t ew a s6 1 % ,m u c hh i g h e rt h a nh a sb e e n
documented for chronic cases in low- and middle-income
countries when DOTS-Plus is not implemented and treat-
ment with second-line drugs is limited or not available [34–
36]. At US$200–US$250 per DALY gained, DOTS-Plus in this
setting is cost-effective when compared with benchmarks that
are widely used to assess intervention cost-effectiveness, such
as a cost per DALY gained of less than per capita gross
national income (US$1,080 in the Philippines) or one to three
times gross domestic product per capita [44,45].
The cure rate was towards the upper end of the 40%–75%
range observed in other resource-limited settings where
second-line drugs are used [8,9,11,13]. Considering the
extensive drug resistance (62% of patients were resistant to
 5 drugs), the frequency of adverse events, and the fact that
most patients were chronic cases and had already received
three or more previous treatments, the cure rate can be
considered to be relatively good. In fact, it could be argued
that given the frequency and nature of some adverse events
(e.g., hearing loss, which is usually irreversible), the default
Table 2. Treatment Outcomes for Patients Enrolled in DOTS-Plus, 1 April 1999 to 31 March 2002
Treatment Outcome Entire Cohort (n ¼ 117) Chronic Cases (n ¼ 90) Retreatment Cases (n ¼ 22) New Cases (n ¼ 5)
Number Percent Total Number Percent Total Number Percent Total Number Percent Total
Cured 70 60 57 63 11 50 2 40
Completed treatment 1 1 1 1 – – – –
Treatment failed 12 10 8 9 4 18 – –
Died 18 15 16 18 1 5 1 20
Defaulted 16 14 8 9 6 27 2 40
Transferred out – – –– –– – –
All 117 100 90 100 22 100 5 100
DOI: 10.1371/journal.pmed.0030352.t002
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Adverse Event
a Number (Percent)
of Patients
Affected
Number
of
Events
Mean Events
per Patient
Affected
Mean Events per
Patient across
Entire Cohort
Drugs Suspected
b
Minor side-effects Nausea 71 (61%) 163 2.3 1.4 E (5), Z (25), Km (1), Cm (1),
O (14), Cx (5), Sp (4), L (4),
Et/Pt (77), Cs (4), PAS (75)
Dizziness 66 (56%) 112 1.7 1.0 E (1), Z (1), S (8), Km (31),
Cm (4), O (21), Cx (5), Sp (7),
L (13), Et/Pt (29), Cs (42), PAS (2)
Insomnia 57 (49%) 98 1.7 0.8 S (1), O (64), Cx (13), Sp (7),
L (11), Et/Pt (4), Cs (34)
Abdominal pain 46 (39%) 89 1.9 0.8 E (2), Z (1), O (11), Cx (2), Sp (1),
L (2), Et/Pt (27), Cs (1), PAS (39)
Diarrhea 45 (38%) 90 2.0 0.8 Z (1), Cm (1), O (8), L (1),
Et/Pt (2), PAS (78)
Headache 38 (32%) 59 1.5 0.5 Z (3), Km (3), O (18), Cx (5), Sp (2),
L (1), Et/Pt (17), Cs (30), PAS (1)
Arthralgia 36 (31%) 55 1.5 0.5 E (5), Z (29), Cm (1), O (1),
Sp (1), Et/Pt (10), Cs (3), PAS (10)
Elevated uric acid 36 (31%) 63 1.8 0.5 Z (51), E (5), Cm (2), Km (2), Et/Pt (4),
O (2), Cs (1), PAS (2), Sp (1)
Peripheral neuropathy 32 (27%) 52 1.6 0.4 E (1), Z (1), S (7), Km (6), Cm (4),
O (1), Sp (1), L (1), Et/Pt (12),
Cs (31), PAS (1)
Fever 31 (26%) 43 1.4 0.4 E (5), Z (3), O (4), Cx (1), PAS (12)
Vertigo/tinnitus 28 (24%) 39 1.4 0.3 S (6), Km (24), Cm (3), O (1),
Cs (3), PAS (2)
Anorexia (loss of appetite) 27 (23%) 41 1.5 0.4 E (1), Z (1), O (2), L (1), Et/Pt (26),
Cs (1), PAS (21)
Muscle pain 22 (19%) 35 1.6 0.3 Z (8), Km (2), O (6), Cx (2), Sp (2),
L (3), Cs (5)
Photophobia 18 (15%) 20 1.1 0.2 Et/Pt (18), Cm (2)
Generalized weakness 15 (13%) 20 1.3 0.2 S (1), K (3), Cm (2), O (3), L (1),
Et/Pt (1), Cs (2), PAS (2)
Pain at site of injection 15 (13%) 15 1.0 0.1 S (1), Km (12), Cm (2)
Blurred vision 14 (12%) 15 1.1 0.1 E (3), Et/Pt (10), Cs (2)
Flu-like symptoms 13 (11%) 15 1.2 0.1 Z (2), O (1), Cx (2), Sp (2), PAS (1)
Decreased K, Ca, Mg 10 (9%) 18 1.8 0.2 Z (3), Cm (6), Cs (2), Cip (1),
Et/Pt (2), PAS (4), Km (1)
Metallic taste 10 (9%) 11 1.1 0.1 Et/Pt (10)
Major side-effects
c Psychosis 11 (9%) 14 1.3 0.1 O (4), Sp (1), L (2), Cs (12)
Depression
d 10 (9%) 14 1.4 0.1 O (4), Cx (1), L (2), Et/Pt (2),
Cs (9), PAS (1)
Barter’s syndrome 3 (3%) 3 1.0 0.03 Cm (2), PAS (1)
Toxic reactions Hearing loss 22 (19%) 33 1.5 0.3 S (5), Km (26), Cm (1)
Arthritis/gout 20 (17%) 30 1.5 0.3 E (2), Z (23), Et/Pt (1), Cs (1), PAS (2)
Palpitation 15 (13%) 21 1.4 0.2 Z (1), O (10), Cx (2), Sp (3), L (5), Cs (3)
Elevated ALT 5 (4%) 6 1.2 0.1 Et/Pt (1), S (1), Z (1), PAS (1), Km (1)
Elevated creatinine 3 (3%) 3 1.0 0.03 S (1), Km (1)
Hypersensitivity
reactions
Rash 22 (19%) 28 1.3 0.2 Z (2), S (1), Km (2), O (5), Cx (2),
Sp (2), L (4), Et/Pt (5), PAS (8)
Bronchospasm 23 (20%) 42 1.8 0.4 NA
Anaphylaxis with angioedema 1 (1%) 1 1.0 0.4 S (1)
Not drug related Hemoptysis 18 (15%) 20 1.1 0.1 NA
Cor pulmonale 6 (5%) 6 1.0 0.1 NA
Tires easily 1 (1%) 1 1.0 0.01 NA
Herpes zoster 1 (1%) 1 1.0 0.01 NA
All types of adverse
event
Minor and major side-effects,
toxic reactions, hypersensitivity
reactions, and events not
related to drugs
112 (96%) 1,276 NA 10.9 See above in this column for range
of drugs causing adverse events
aNot mutually exclusive. Patients could have two or more side effects simultaneously.
bFor a given adverse event (e.g., nausea), the sum of the numbers in this column exceeds the number of times the adverse event occurred when more than one drug was suspected of
causing the adverse event on one or more occasions. The sum in this column is less when a suspected drug was not identified for some events.
cMajor side effects require hospitalization and may be life-threatening.
dThere were three suicide attempts in two patients.
Amk, amikacin; Cm, capreomycin; Cs, cycloserine; Cx, ciprofloxacin; E, ethambutol; Et, ethionamide; Km, kanamycin; L, levofloxacin; O, ofloxacin; PAS, para-aminosalicylic acid; Pt,
prothionamide; S, streptomycin; Sp, sparfloxacin; Z, pyrazinamide.
DOI: 10.1371/journal.pmed.0030352.t003
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Analysis of DOTS-Plus in the Philippinesrate of 14% could easily have been higher. The fact that
counselling and education about adverse events was provided
by MMC staff and that many adverse effects were categorized
as ‘‘minor’’ may explain why most patients experiencing
adverse events did not default. For chronic cases, a further
important reason is that DOTS-Plus treatment is regarded as
the last chance of being cured of TB; this may also explain
why the default rate was lower than for new and retreatment
cases, a ﬁnding that warrants further investigation.
Four measures have now been implemented to reduce the
default rate: provision of ancillary drugs for management of
adverse events free of charge to patients (previously, patients
needed to pay for these drugs); decentralization of treatment
so that it is available closer to where patients live, thus
reducing costs; provision of psychosocial support; and use of
patient incentives and enablers. Preliminary data suggest that
these measures will lower the default rate to about 7%. This
would also improve cost-effectiveness to about US$150 per
DALY gained from a health system perspective and to about
US$200 from a societal perspective.
The cost to the health system, at US$3,355 per patient, was
more than the US$2,381 reported for the national DOTS-Plus
programme in Peru, mostly due to the higher cost of drugs
(US$1,557 versus US$824 in Peru) [8]. However, since higher
costs were accompanied by higher cure rates in the
Philippines (61% versus 48%), cost-effectiveness was similar,
at about US$200 per DALY gained.
The study has several limitations. The project identiﬁed a
Table 4. Drugs Used for DOTS-Plus Cohort, and Main Adverse Events with Which They Were Associated
Name of Drug Class of Drug Number of
Patients
Treated
Adverse Events in Which Drug
Was Suspected to Be the Cause
a
Ethambutol Ethelynediamine 41 Arthralgia (5), fever (5), nausea (5), elevated uric acid (5), blurred vision (3)
Pyrazinamide Pyridines or isonicotinic acid derivatives 85 Elevated uric acid (51), arthralgia (29), nausea (25), arthritis (23), muscle pain (8)
Streptomycin Aminoglycoside 47 Dizziness (8), peripheral neuropathy (7), vertigo/tinnitus (6), hearing loss (5),
anaphylaxis (1)
Kanamycin Aminoglycoside 88 Dizziness (31), hearing loss (26), vertigo/tinnitus (24), pain at injection (12),
peripheral neuropathy (6)
Capreomycin Cyclic polypeptide 20 Decreased K, Ca, Mg (6), peripheral neuropathy (4), dizziness (4),
vertigo/tinnitus (3), weakness (2)
Ofloxacin Fluoroquinolone 84 Insomnia (64), dizziness (21), headache (18), nausea (14), abdominal pain (11)
Ciprofloxacin Fluoroquinolone 17 Insomnia (13), dizziness (5), headache (5), nausea (5), abdominal pain (2)
Sparfloxacin Fluoroquinolone 14 Dizziness (7), insomnia (7), nausea (4), palpitations (3), rash (2)
Levofloxacin Fluoroquinolone 23 Dizziness (13), insomnia (11), palpitations (5), nausea (4), rash (4)
Ethionamide/
Prothionamide
Thionamide/Carbotionamides group,
derivatives of isonicotinic acid
41 Nausea (77), dizziness (29), abdominal pain (27), anorexia (26),
photophobia (18)
Cycloserine Analog of D-alanine 112 Dizziness (42), insomnia (34), peripheral neuropathy (31),
headache (30), psychosis (12)
PASER Salicyclic acid, anti-folase 95 Diarrhea (78), nausea (75), abdominal pain (39), anorexia (21), fever (12)
Responsible drug not identified NA NA Abdominal pain (3), fever (3), rash (3), lymphadenopathy (3), muscle ache (2)
NOT drug-related NA 41 Bronchospasm (41), hemoptysis (20)
aThe top five adverse events associated with each drug are shown. Full details (i.e., the full list of adverse events) are available from authors upon request, or can be calculated from the
data in Table 3. The frequency with which a drug was suspected of causing each adverse event is provided in brackets. For a given adverse event (e.g., nausea), the sum of the numbers in
this column exceeds the number of times the adverse event occurred when more than one drug was suspected of causing the adverse event on one or more occasions.
DOI: 10.1371/journal.pmed.0030352.t004
Table 5. Average Cost per Patient Treated in 2002 US$ (Percent Column Total), DOTS-Plus Project
Cost Item Health System
a Patients/Families
Drugs
b 1,557 (46) –
Programme management 382 (11) –
Data management 330 (10) –
Training 258 (8) –
Laboratory tests and X-rays
c 211 (6) –
Contact tracing 182 (5) –
253 clinic visits for DOT and monitoring 116 (3) 471 (56)
Seven days hospitalization 107 (3) 33 (4)
Other 212 (6) 333 (40)
d
Total cost per patient 3,355 837
aTotal of percentages in this column does not sum to 100 due to rounding.
bAlmost 50% of the US$1,557 was accounted for by one drug, PASER.
c34 smears, 27 cultures, two drug susceptibility tests, three X-rays.
dThese costs were mainly for board and lodging among patients not resident in or near the MMC.
DOI: 10.1371/journal.pmed.0030352.t005
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Analysis of DOTS-Plus in the Philippineslarge number of eligible patients who were not enrolled (53
out of 171). However, ten of these patients were enrolled after
April 2002 and our comparison with the study cohort showed
no signiﬁcant differences in demographic or clinical charac-
teristics besides residence and the percentage of patients who
were resistant to ﬁve or more drugs (with more severe drug
resistance among those enrolled). A major reason for non-
enrollment—lack of funding at the time the patients were
identiﬁed—was clearly recognized by MMC staff. The relapse
rate is not yet known, though long-term follow-up is
occurring. The applicability of the data to people with HIV
infection and children is unknown, since the patient cohort
was restricted to adults and rates of HIV infection were
believed to be low. As in previous studies, data about the
outcomes and costs associated with chronic cases of MDR-TB
when DOTS-Plus treatment is not available were scarce.
Nonetheless, considerable efforts were made to collect
relevant data locally, in addition to making use of long-term
follow-up studies from other countries. While recognizing the
shortcomings of these data, we believe that they are the best
that could be obtained without a long-term study. Further-
more, the costs reported in the absence of DOTS-Plus were
very low; if anything we may have overestimated the increase
in costs that occurs when DOTS-Plus treatment is made
available.
Strengths of the study include the fact that it is only the
second to our knowledge to provide evidence of the
feasibility, effectiveness, cost, and cost-effectiveness of
DOTS-Plus in a low- or middle-income country, and the ﬁrst
to report empirical data on the costs of treatment when
individualised regimens are used. To our knowledge, it is also
the ﬁrst study to document costs from a patient and
household perspective as well as a health systems perspective,
the ﬁrst from a GLC-monitored DOTS-Plus pilot project, and
the ﬁrst from Asia.
Nationwide expansion of DOTS-Plus in the Philippines is
likely to start in 2006 or early 2007, following a successful
round ﬁve application to the Global Fund to ﬁght AIDS, TB,
and Malaria (GFATM) that was approved in December 2005.
Achieving treatment outcomes similar to those at MMC at
other sites will require four elements of the MMC project to
be replicated: a high level of commitment from all partners;
technical support from international institutions such as
WHO and the GLC; a clinic team that is highly motivated and
committed to providing DOT, managing adverse events, and
following up on defaulters; and a similar level of resources
(i.e., about US$3,500 per patient enrolled in treatment). In
parallel it is important to improve treatment for drug-
susceptible cases in the private sector (the source of more
than 75% of cases in the cohort that we studied), to prevent
the problem of MDR emerging in the ﬁrst place. Encourag-
ingly, nationwide expansion of the public private mix DOTS
(PPMD) strategy is well under way [4].
Overall, our study demonstrates that treatment of patients
with MDR-TB using the DOTS-Plus strategy and individu-
alised drug regimens can be feasible, comparatively effective,
and cost-effective in low- and middle-income countries.
Success with nationwide scaling up in the Philippines will
now depend primarily on the application of lessons learned
during this [and the overall] DOTS-Plus experience.
Supporting Information
Protocol S1. Provides Details of the Variables, Parameters, and
Parameter Distributions Used for the Effectiveness and Cost-
Effectiveness Analysis
Found at DOI: 10.1371/journal.pmed.0030352.sd001 (68 KB DOC).
Protocol S2. Provides Data Comparing the Patients Who Were
Enrolled in Treatment with the 53 Patients Who Were Eligible for
Treatment but Who Were Not Enrolled
Found at DOI: 10.1371/journal.pmed.0030352.sd002 (49 KB DOC).
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Analysis of DOTS-Plus in the PhilippinesEditors’ Summary
Background. Tuberculosis (TB) causes the death of some 2 million
people each year. An estimated one in three people worldwide are
infected with Mycobacterium tuberculosis, the bacterium that causes the
disease. Because single-drug treatment leads to treatment failure and
antibiotic resistance, treatment for active TB is complicated, usually
involving four different antibiotics, at least two of which are continued
for six months or more. The World Health Organization (WHO)
recommends a specific strategy (DOTS) for diagnosing and treating TB
(see Web link below).
The DOTS approach includes standard regimens of first-line drugs
which cure about 90% of patients with drug-susceptible TB, and which
cost as little as US$10 per patient. Unfortunately, TB resistance to at least
two of the most effective DOTS drugs has developed at sites in both
industrialized and developing countries, causing approximately 460,000
cases of multidrug-resistant TB (MDR-TB) per year. Second-line anti-
biotics, which tend to be more expensive or more difficult to take, can
effectively treat many cases of MDR-TB. ‘‘DOTS-Plus’’ programmes, which
use combinations of first- and second-line drugs to treat MDR-TB, are
therefore becoming increasingly important in controlling TB worldwide.
A recent study found DOTS-Plus strategies to be cost-effective in Peru,
but cure rates of MDR-TB were relatively low.
Why Was This Study Done? Because the use of second-line antibiotics
is costly and the treatment of MDR-TB has a higher failure rate than that
of fully drug-susceptible TB, policymakers responsible for allocation of
limited healthcare resources need information on how well DOTS-Plus
programmes work and how much they cost to operate. This study was
undertaken to assess the feasibility, effectiveness, and cost-effectiveness
of a DOTS-Plus project in the Philippines, a lower middle–income country
with a high rate of TB and approximately 25,000 cases of MDR-TB.
What Did the Researchers Do and Find? The researchers reported
on a DOTS-Plus pilot project at Makati Medical Center in Manila,
analyzing information from 118 patients enrolled in the project between
1999 and 2002. The diagnosis of MDR-TB was based on laboratory
culture and antibiotic resistance testing of specimens from patients who
had continued symptoms of TB following DOTS treatment, or other
evidence of possible MDR-TB. Patients were treated with five-drug
combinations individually selected based on resistance testing results,
and administered under direct observation. After cultures had remained
consistently negative for six months, patients were switched to a four-
drug regimen with intermittent clinic observation until cultures
remained negative for at least 18 months.
Cost-effectiveness was assessed by comparing the costs and effects
of the project to the costs and effects that would have applied in the
absence of the project, namely, no treatment of MDR-TB (except what
patients could have purchased privately), or standard first-line DOTS
treatment (which would not cure the majority of patients with MDR-TB,
and is associated with a high chance of relapse in those who do appear
cured). Costs of the DOTS-Plus project were based on expenditure
records, project records, and interviews with staff, patients, and funding
agencies. Effects of the project were based on treatment outcomes
observed among enrolled patients, as well as on data on long-term
outcomes among patients treated for MDR-TB in the US who were
followed for up to ten years. Treatment costs for the situation in which
no DOTS-Plus project exists were estimated using national data reported
to WHO, as well as questionnaires administered to local patients in
whom DOTS treatment had failed. Treatment outcomes where DOTS-
Plus is not available were estimated from studies done in other TB-
affected countries.
The researchers found that the cure rate of MDR-TB in this project
was 61%. The cost per patient treated was US$4,192. They also calculated
that the cost-effectiveness of the DOTS-Plus strategy was US$242 per
disability-adjusted life year (DALY) gained, of which US$179 was paid by
the healthcare system.
What Do These Findings Mean? The cure rate for MDR-TB in this
project compares favourably to rates in other resource-limited settings
where second-line TB drugs are used, and is much higher than in areas
where these drugs are not available. From the standpoint of efficacy and
patient well-being, then, this study supports the necessity of DOTS-Plus
treatment. In purely economic terms, the cost of US$200–US$250 per
DALY gained is cost-effective in comparison with other healthcare
interventions. Specifically, because the gross national income per person
in the Philippines is US$1,080, someone who can return to work
following MDR-TB treatment costing US$250 per year gained of working
life will provide work that is worth four times more, on average, than the
cost of the treatment.
Although this study provides encouraging confirmation that DOTS-
Plus programmes can be effective and cost-effective in a resource-
limited setting, these findings are subject to several limitations. First, the
data used to estimate treatment outcomes and the costs associated with
chronic MDR-TB when DOTS-Plus treatment is not available were limited.
Also, the pilot project in this study included only 118 of 171 eligible
patients, leaving open the possibility that the other 53 patients might
have had different outcomes. In addition, the long-term relapse rate in
the treated patients is unknown. Finally, the conclusion that one model
programme is effective does not mean that other programmes will do
well under less favourable circumstances. Nonetheless, as MDR-TB
continues to spread in the developing world, a good example is good
news. A Perspective by Paul Garner and colleagues in this issue of PLoS
Medicine (DOI: 10.1371/journal.pmed.0030350) discusses the study
further.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030352.
  Basic information about tuberculosis can be found on the Web site of
the US National Institute of Allergy and Infectious Diseases (NIAID)
  The Web site of the World Health Organization’s Stop TB department
outlines both the DOTS and DOTS-Plus strategies
  TB Alert, a UK-based charity that promotes TB awareness worldwide,
has information on TB in several European, African, and Asian
languages
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